Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 7/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25911009 | 0.91 | PDK1 (0.56) | PDK1ALDH1A1NPSR1HDAC8HTT | |
| SCHEMBL25910975 | 0.87 | PDK1 (0.48) | PDK1ALDH1A1NPSR1HDAC8HTT | |
| SCHEMBL25910983 | 0.86 | KDM4E (0.52) | PDK1ALDH1A1NPSR1HDAC8HTT | |
| SCHEMBL25910996 | 0.86 | ALDH1A1 (0.47) | PDK1ALDH1A1NPSR1HDAC8HTT | |
| SCHEMBL25910972 | 0.85 | ALDH1A1 (0.53) | PDK1ALDH1A1NPSR1HDAC8HTT | |
| SCHEMBL25910976 | 0.85 | ALDH1A1 (0.62) | PDK1ALDH1A1NPSR1HDAC8HTT | |
| SCHEMBL25911188 | 0.85 | ALDH1A1 (0.51) | PDK1ALDH1A1NPSR1HDAC8HTT | |
| SCHEMBL25911033 | 0.85 | ALDH1A1 (0.48) | PDK1ALDH1A1NPSR1HDAC8HTT | |
| SCHEMBL25911165 | 0.84 | ALDH1A1 (0.49) | PDK1ALDH1A1NPSR1HDAC8HTT | |
| SCHEMBL25911190 | 0.84 | ALDH1A1 (0.52) | PDK1ALDH1A1NPSR1HDAC8HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233541-A1 | SUBSTITUTED BENZAMIDES AS MODULATORS OF TREX1 | CONSTELLATION PHARMACEUTICALS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230233541-A1 | SUBSTITUTED BENZAMIDES AS MODULATORS OF TREX1 | CONSTELLATION PHARMACEUTICALS, INC. | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233541-A1 | SUBSTITUTED BENZAMIDES AS MODULATORS OF TREX1 | TREH, BRIX1, GBA1 | PDK1 1949/4885ALDH1A1 327/4885KCNMA1 1152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.